Author:
Heaf James G.,van Biesen Wim
Abstract
IN BRIEF
Most guidelines advise against the use of metformin in uremia because of an enhanced risk for lactic acidosis (LA). However, there exists no firm theoretical or experimental evidence demonstrating a negative effect of metformin on p-lactate metabolism nor any epidemiological support for an increased risk of LA. Because metformin reduces cardiovascular events and mortality in type 2 diabetes, there is no justification for maintaining azotemia as a contraindication to metformin treatment.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference32 articles.
1. Epidemiology of adverse drug reactions to phenformin and metformin;Bergman;BMJ,1978
2. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus;Stumvoll;N Engl J Med,1995
3. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus;Cusi;J Clin Endocrinol Metab,1996
4. Efficacy of metformin in the treatment of NIDDM;Johansen;Diabetes Care,1999
5. Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + phenformin lowers the lacticemia levels in type-2 diabetics (NIDDM);Velussi;Clin Ter,1992
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献